GSDMC (Gasdermin C)

Finally, our translational pathway should be prioritized with orthogonal confirmation, interference testing, and clinically meaningful reporting to be adopted in the field of laboratory medicine. This supports reproducible biomarkers for clinical decision-making.

Finally, we validated the effect of the super-enhancer activity on PLAU and GSDMC expression. Overall, our study identified super-enhancer-based biomarkers for predicting survival and immunotherapy efficacy in colorectal cancer.

Targeting pyroptosis is a novel therapeutic avenue for PN. This review synthesizes current mechanistic understanding, evaluates preclinical therapeutic strategies, and delineates crucial future directions, including elucidating gasdermin diversity, validating PANoptosis, and bridging the translational divide, thereby accelerating their application for patients suffering from PN.

Bulk gene expression profiling and deconvolution analysis for patients with cytoplasmic GSDMD-N-terminal expression revealed downregulation of "Don't eat me" signaling genes, upregulation of many RNA genes, decreased frequency of "Inflammatory" lymphoma microenvironment subtype, increased abundance of prognostically favorable cell states and ecotypes, and decreased abundance of T cell exhaustion state. In summary, this study showed distinct cellular and subcellular patterns of three gasdermin proteins and their associated immune response phenotypes and prognostic effects, with implications for novel therapeutic strategies for B-cell lymphoma.

Mitoxantrone, a promising inducer, is encapsulated in platelet membrane-hybridized liposomes to enhance targeted delivery and therapeutic efficacy...This activated Caspase8 and the NLRP3 inflammasome, leading to GSDMC cleavage and initiating pyroptosis. Collectively, this study provides an innovative pyroptosis therapy strategy combining physical treatment and chemotherapy for BLBC and other refractory diseases.

Overall, our results suggest a significant involvement of the GSDM group in the pathogenesis of glioma. GSDMB, GSDMC, GSDMD, and GSDME have been identified as potential prognostic and predictive markers for glioma, while GSDMs show promise as therapeutic targets for this type of brain tumor.

Molecular docking studies support curcumin's direct binding to several pyroptosis-associated proteins, including NLRP3, AMPK, caspase-1, and Smurf2. These context-dependent regulatory effects underscore the therapeutic potential of curcumin as both an inflammasome suppressor in inflammatory diseases and a pyroptosis inducer in cancer.

Finally, qRT-PCR results further confirmed our findings. We successfully developed a predictive feature model consisting of seven NARCDs, offering fresh insight into the prognostic evaluation of CRC patients and establishing a theoretical basis for crafting personalized treatment approaches.

This review highlighted the regulatory roles and molecular mechanisms of the GSDMs family in cell death, inflammation, and immunity, and underscores their function as central hubs in these interconnected processes. Further elucidation of GSDM biology will deepen our understanding of cellular homeostasis and disease, and support the development of precise therapies.

Moreover, rigosertib induced caspase-1 activation and gasdermin cleavage leading to Nod-like receptor pyrin domain-containing 3 (NLRP3)-dependent inflammatory responses in human lung cancer organoids. Our results suggest that rigosertib may effectively inhibit RAS-MAPK signaling and reprogram the tumor immune environment, presenting the potential for a potent therapeutic strategy in cancer treatment.

By dissecting the interplay among pyroptosis induction, biological processes such as inflammasome activation and gasdermin cleavage, and subsequent immune reprogramming, we provide a thorough overview of the action mechanisms of metal complex-based pyroptosis inducers. This understanding has inspired the rational development of novel anticancer metal complexes that can remodel the tumor microenvironment and synergize with immunotherapies.

The FPM-EM combination offers promising new therapeutic options for HCC, addressing the limitations of TACE. Furthermore, the FPM-EM platform can be extended to the interventional therapy of other tumors and adapted to incorporate various drugs and nano-/micro-materials, highlighting the strong potential for future clinical translation.